1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

Autor: Goode, D., Keerthikumar, S., Gupta, S., Joshua, A.M., Emmett, L., Crumbaker, M., Singer, T., Lam, E., Fernandez, L., Jimenez, E., Zhang, D., Lin, Y., Wenstrup, R.J., PASAM, A., Hicks, R., Kong, G., Hamid, A., Sandhu, S.K.
Zdroj: In Annals of Oncology October 2023 34 Supplement 2:S988-S989
Databáze: ScienceDirect